beta

FTSV

Forty Seven, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Market Cap: 1.87 Billion

Primary Exchange: NASDAQ

Website: http://www.fortyseveninc.com

Shares Outstanding: 48 Million

Float: 27 Million

Dividend: (%)

Beta: 1.71694906027094

Sector: Health Technology

Industry: Pharmaceuticals: Major

Ethical Flags

Longest drawdown: 257 trading days

From: 2018-12-14 To: 2019-12-06

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud